Consolidated Q2 FY27: revenue up 19.6%, profit after tax up 27.4%, EBITDA margin rises
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Smallcap 250 and 4.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue from operations was INR 873.9 crore, up 19.6% from INR 730.6 crore in Q2 FY26; profit after tax was INR 193.9 crore, up 27.4% from INR 152.2 crore in Q2 FY26. EBITDA margin rose to 32.1% from 30.7%. The board declared a second interim dividend of INR 5 per share and approved up to INR 49.5 crore for Dubai, including up to INR 30 crore for Ghana. Director appointment pending approval. EPS restated for bonus shares.
Profit growth, margin improvement and the INR 5 dividend may support the stock, while the Dubai funding commitment adds cash outflow risk.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.